MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

Erik A. Lippa; Joel S. Schuman; Eve J. Higginbotham; Michael A. Kass; Robert N. Weinreb; Gregory L. Skuta; David L. Epstein; Blake Shaw; Daniel J. Holder; Deni A. Deasy; Jacob T. Wilensky

doi:10.1016/S0161-6420(91)32295-4

MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

Erik A. Lippa, Joel S. Schuman, Eve J. Higginbotham, Michael A. Kass, Robert N. Weinreb, Gregory L. Skuta, David L. Epstein, Blake Shaw, Daniel J. Holder, Deni A. Deasy, Jacob T. Wilensky

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

Original language	English
Pages (from-to)	308-313
Number of pages	6
Journal	Ophthalmology
Volume	98
Issue number	3
DOIs	https://doi.org/10.1016/S0161-6420(91)32295-4
State	Published - Jan 1 1991

Access to Document

10.1016/S0161-6420(91)32295-4

Cite this

@article{41d34afae93b4e6ba8ad5932ddb535d3,

title = "MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors",

abstract = "Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.",

author = "Lippa, {Erik A.} and Schuman, {Joel S.} and Higginbotham, {Eve J.} and Kass, {Michael A.} and Weinreb, {Robert N.} and Skuta, {Gregory L.} and Epstein, {David L.} and Blake Shaw and Holder, {Daniel J.} and Deasy, {Deni A.} and Wilensky, {Jacob T.}",

year = "1991",

month = jan,

day = "1",

doi = "10.1016/S0161-6420(91)32295-4",

language = "English",

volume = "98",

pages = "308--313",

journal = "Ophthalmology",

issn = "0161-6420",

number = "3",

}

TY - JOUR

T1 - MK-507 versus Sezolamide

T2 - Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

AU - Lippa, Erik A.

AU - Schuman, Joel S.

AU - Higginbotham, Eve J.

AU - Kass, Michael A.

AU - Weinreb, Robert N.

AU - Skuta, Gregory L.

AU - Epstein, David L.

AU - Shaw, Blake

AU - Holder, Daniel J.

AU - Deasy, Deni A.

AU - Wilensky, Jacob T.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

AB - Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=0026032045&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(91)32295-4

DO - 10.1016/S0161-6420(91)32295-4

M3 - Article

C2 - 2023750

AN - SCOPUS:0026032045

SN - 0161-6420

VL - 98

SP - 308

EP - 313

JO - Ophthalmology

JF - Ophthalmology

IS - 3

ER -

MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this